Literature DB >> 20646743

Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma.

Robert Abouassaly1, Shabbir M H Alibhai, Nasir Shah, Narhari Timilshina, Neil Fleshner, Antonio Finelli.   

Abstract

OBJECTIVES: To review the surgical management of upper tract urothelial carcinoma (UTUC) on a population level. UTUC accounts for 5% of urothelial malignancies, making it less amenable to single-center reporting. Complete nephroureterectomy is the standard of care, and increasing evidence has shown that a suboptimal surgical technique is associated with an adverse prognosis.
METHODS: We obtained information for all patients diagnosed with UTUC (n = 830) and those treated surgically (n = 680) in the province of Ontario, Canada from the Ontario Cancer Registry from 1995 to 2004. Demographic, treatment, and vital status information was obtained for all patients, and pathology reports were available for 422 patients. The primary outcome was overall survival. The secondary outcomes included measures of surgical quality (ie, number of lymph nodes sampled, ureteral length excised, surgical margin status, and 30-day mortality) and disease-specific survival.
RESULTS: The unadjusted 5-year overall survival rate was 57.2%, with a median survival of 72.5 months. For those treated surgically, the 30-day mortality rate was 1.8%, and the positive surgical margin rate was 8.5%. Lymph nodes were identified in only 27% of the specimens, with a median yield of 1 (range 1-15). An estimated 25.8% of patients might have undergone incomplete ureteral resection at the time of nephroureterectomy.
CONCLUSIONS: UTUC is a lethal malignancy, with nearly one half the patients dying within 5 years. Furthermore, lymphadenectomy was rarely performed and approximately one fourth of patients might have undergone incomplete ureterectomy. The published outcomes from "centers of excellence" do not appear to reflect the surgical quality seen on a population level for this rare, but significant, malignancy.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20646743     DOI: 10.1016/j.urology.2010.04.020

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  37 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).

Authors:  Francesco Soria; Marco Moschini; Andrea Haitel; Gregory J Wirth; Jose A Karam; Christopher G Wood; Morgan Rouprêt; Vitaly Margulis; Pierre I Karakiewicz; Alberto Briganti; Jay D Raman; Solene-Florence Kammerer-Jacquet; Romain Mathieu; Karim Bensalah; Yair Lotan; Mehmet Özsoy; Mesut Remzi; Kilian M Gust; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-06-07       Impact factor: 4.226

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

4.  Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study.

Authors:  Bjarte Almås; Stein Øverby; Ole J Halvorsen; Lars A R Reisæter; Jørg Assmus; Birgitte Carlsen; Anders Loe; Christian Beisland
Journal:  World J Urol       Date:  2019-05-23       Impact factor: 4.226

5.  Mining the data on UTUC management.

Authors:  Michael J Leveridge
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

6.  Diffusion-weighted MRI as a potential imaging biomarker reflecting the metastatic potential of upper urinary tract cancer.

Authors:  Y Uchida; S Yoshida; S Kobayashi; F Koga; J Ishioka; S Satoh; C Ishii; H Tanaka; Y Matsuoka; N Numao; K Saito; H Masuda; Y Fujii; K Kihara
Journal:  Br J Radiol       Date:  2014-07-30       Impact factor: 3.039

7.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

8.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

9.  Serum metabolomic analysis of human upper urinary tract urothelial carcinoma.

Authors:  Pengchao Li; Jun Tao; Dandan Wei; Xiao Yang; Zhaoguang Lu; Xiaheng Deng; Yiong Cheng; Jinbao Gu; Xuejian Yang; Zengjun Wang; Qiang Lu; Junsong Wang; Changjun Yin
Journal:  Tumour Biol       Date:  2015-04-28

10.  Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report.

Authors:  Soichiro Yoshida; Shuichiro Kobayashi; Fumitaka Koga; Junichiro Ishioka; Chikako Ishii; Hiroshi Tanaka; Yasukazu Nakanishi; Yoh Matsuoka; Noboru Numao; Kazutaka Saito; Hitoshi Masuda; Yasuhisa Fujii; Kazunori Kihara
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.